Scientists harness immune system to prevent lymphoma relapse

October 18, 2012

UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.

The University of Manchester researchers, who were funded by the charity Leukaemia & Lymphoma Research, have shown that, when used in conjunction with , the new drug is potentially four times more likely to lead to long-term survival than radiotherapy alone.

Relapse is a common fate for many and new treatments are desperately needed. The new research, which is published online in Blood, the Journal of the American Society of Hematology (ASH), shows that the chemical R848 can be used to prime the to fight .

R848 is a chemical which signals to certain molecules known as receptors found on the surface of immune cells, triggering them into action. Receptors play a key role in the function of the immune cell by recognising harmful agents and instructing the cell to respond. It was shown that injections of R848 can generate a rapid expansion of specific anti-lymphoma immune cells known as 'killer T cells'.

Dr Simon Dovedi, of the University of Manchester's School of Cancer and Enabling Sciences, who led the research, said: "Excitingly we think that R848 could be capable of giving patients a protective immunological memory by generating lymphoma-specific anti-tumour cells. This could be the key to ensuring long-term survival."

The Manchester team tested injections of R848, in combination with radiotherapy, in the laboratory on mice with lymphoma. It was found to have few side effects, with 100% of mice achieving long-term survival compared to just 28% of those mice which were treated with radiotherapy alone. In those mice that achieved long-term survival through treatment with R848 and radiotherapy, any re-introduction of cancer was completely rejected by the immune system in 75% of cases. These successful laboratory results mean that it could soon be used in early phase clinical trials for patients with lymphoma.

Professor Chris Bunce, Research Director of Leukaemia & Lymphoma Research, said: "While it is still early and this treatment has not yet been tested in humans, these results are hugely promising. One of the major obstacles to long-term successful treatment for many types of has been relapse after initial successful treatment. with R848 can prime T cells to recognise various tumour-associated antigens, protecting patients from the return of the cancer."

Explore further: Researchers’ blood cancer breakthrough

More information: The report is published online in the journal Blood, the Journal of the American Society of Hematology (ASH), under the title 'Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma'.

Related Stories

Researchers’ blood cancer breakthrough

August 10, 2011
Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed.

Researchers' discovery revives hope in promising lymphoma treatment

October 15, 2012
(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered the mechanism by which an experimental drug known as GCS-100 removes from lymphoma cells a protein that prevents the cells from ...

Survival niche for cancer cells

June 6, 2011
Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply ...

Researchers find potential key to new treatment for mantle cell lymphoma

July 18, 2012
Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable ...

Southampton scientists to investigate ways to prevent life-threatening complications in transplant patients

August 21, 2012
Scientists from the University of Southampton have received a grant from the blood cancer charity Leukaemia & Lymphoma Research to explore ways of preventing life-threatening side effects in patients receiving bone marrow ...

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.